Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rivaroxaban plus aspirin for endothelial function in peripheral artery disease
NL-OMON49319Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban and aspirin in arteriosclerosis obliterans, sponsored by Amsterdam University Medical Center. Started Jun 2020; status: active, not recruiting.
02
Drugs
rivaroxabanaspirin
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON49319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49319.